Cutera (NASDAQ:CUTR) Rating Reiterated by Stephens

Stephens reissued their overweight rating on shares of Cutera (NASDAQ:CUTR) in a report issued on Tuesday morning, Benzinga reports. Stephens currently has a $10.00 target price on the medical device company’s stock.

Other research analysts have also issued reports about the company. William Blair upgraded Cutera from an underperform rating to a market perform rating in a research report on Friday, March 22nd. StockNews.com upgraded Cutera to a sell rating in a research report on Friday, May 10th. Finally, Piper Sandler restated a neutral rating and set a $3.00 price target on shares of Cutera in a research report on Friday, June 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Cutera presently has an average rating of Hold and an average target price of $7.67.

Cutera Stock Performance

Shares of Cutera stock opened at $1.51 on Tuesday. The firm has a market capitalization of $30.35 million, a price-to-earnings ratio of -0.21 and a beta of 1.42. Cutera has a fifty-two week low of $1.28 and a fifty-two week high of $21.41. The stock has a 50 day moving average of $2.06 and a 200 day moving average of $2.37.

Cutera (NASDAQ:CUTR) last issued its quarterly earnings data on Thursday, May 9th. The medical device company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.05). The company had revenue of $38.79 million during the quarter, compared to the consensus estimate of $37.17 million. During the same period last year, the firm earned ($1.26) EPS. Analysts forecast that Cutera will post -5.88 EPS for the current year.

Insider Activity at Cutera

In related news, EVP Michael Karavitis sold 24,940 shares of Cutera stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $2.59, for a total value of $64,594.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.42% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its holdings in Cutera by 112.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,363 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 4,430 shares during the period. BNP Paribas Financial Markets raised its stake in Cutera by 7.1% in the first quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock valued at $111,000 after buying an additional 5,017 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Cutera in the third quarter valued at $43,000. PNC Financial Services Group Inc. raised its stake in Cutera by 75.6% in the third quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the medical device company’s stock valued at $132,000 after buying an additional 9,472 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Cutera in the fourth quarter valued at $43,000. 90.70% of the stock is currently owned by hedge funds and other institutional investors.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.